- Home
- CRWD vs GILD Comparison
CRWD vs GILD Comparison
Compare CRWD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRWD | GILD |
|---|---|---|
| Founded | 2011 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.8B | 187.4B |
| IPO Year | 2019 | 2003 |
Fundamental Metrics
Financial Performance| Metric | CRWD | GILD |
|---|---|---|
| Price | $256.31 | $157.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 53 | 28 |
| Target Price | ★ $246.15 | $159.85 |
| AVG Volume (30 Days) | ★ 6.1M | 4.9M |
| Earning Date | 12-01-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 2.09% |
| EPS Growth | N/A | ★ 1684.21 |
| EPS | ★ 0.03 | N/A |
| Revenue | $4,812,005,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $24.84 | $4.36 |
| Revenue Next Year | $22.71 | $6.88 |
| P/E Ratio | $7,953.67 | ★ N/A |
| Revenue Growth | ★ 21.71 | 9.98 |
| 52 Week Low | $174.14 | $114.02 |
| 52 Week High | $786.00 | $160.51 |
Technical Indicators
Market Signals| Indicator | CRWD | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 60.52 |
| Support Level | $178.38 | $142.91 |
| Resistance Level | $286.99 | $158.90 |
| Average True Range (ATR) | 12.32 | 3.75 |
| MACD | -2.67 | 0.55 |
| Stochastic Oscillator | 53.22 | 81.19 |
Price Performance
Historical ComparisonAbout CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).